[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519636":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":70,"collaborators":72,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":20,"enrollmentInfo":85,"targetDuration":20,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":20,"overallStatus":57,"whyStopped":20,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients prostate cancer","Patient with a confirmed diagnosis of prostate cancer will be included before starting any treatment. Recruitment will be carried out by urologists from the urology departments of the CHU of Guadeloupe and the CHU of Rennes.",[12],"Other: Standard care",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Standard care","Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and\u002For assays of any other biological compound of interest strictly related to the specific objectives of the research.\n\nSaliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire",[9],[19],"Extra blood collection, urine collection and saliva collection, questionnaire.",null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Valérie HAMONY-SOTER","CONTACT","+590 590 93 46 77","valerie.soter@chu-guadeloupe.fr",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Eunice NUBRET","+590 590 93 46 86","eunice.nubret@chu-guadeloupe.fr",[32,55],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"CHU of Rennes","NOT_YET_RECRUITING","Rennes","Ille-et-Vilaine","35000","France","FR",{"type":41,"coordinates":42},"Point",[43,44],-1.67431,48.11109,{"lat":44,"lon":43},[47,49,53],{"name":48,"role":24,"phone":25,"phoneExt":20,"email":26},"Valérie Hamony Soter",{"name":50,"role":24,"phone":51,"phoneExt":20,"email":52},"Romain MATHIEU","+33 (0)6 63 69 70 30","romain.mathieu@chu-rennes.fr",{"name":50,"role":54,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":59,"countryCode":20,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"CHU of Guadeloupe","RECRUITING","Pointe-à-Pitre","Guadeloupe","97159",{"type":41,"coordinates":62},[63,64],-61.53459,16.23638,{"lat":64,"lon":63},[67,68],{"name":48,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":69,"role":54,"phone":20,"phoneExt":20,"email":20},"Laurent BRUREAU",{"type":71,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[73],{"name":74,"class":75},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV","100519636","clinical-genetic-and-environmental-determinants-of-prostate-cancer-progression-100519636",false,"NCT06046131","Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.","KP-CARAIBES","Inclusion Criteria:\n\nInclusion criteria:\n\nAdult patients with incident case of prostate cancer Patient consulting the University Hospital of Guadeloupe or the University Hospital of Rennes Patient who resides in the departments of Guadeloupe or Martinique or the community of Saint-Martin or in Britany Patient affiliated or beneficiary of the social security signed consent\n\nExclusion Criteria:\n\nPhysical or mental health judjed by the investigator as precluding participation in the research Protected adults (guardianship, curatorship, safeguard of justice).","MALE","18 Years",{"count":86,"type":87},3000,"ESTIMATED","INTERVENTIONAL",[90],"NA","The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .",[93,94,95,96],"Prostatic Neoplasm","Adenocarcinoma","Neoplasm Recurrence","Neoplasm Metastasis","2025-11-14",{"date":99,"type":100},"2025-11-17","ACTUAL",{"date":102,"type":100},"2023-02-28",{"date":104,"type":87},"2039-02-28",{"name":5,"class":6},2]